244 related articles for article (PubMed ID: 19020388)
61. Growth hormone replacement therapy improves hypopituitarism-associated hypoxemia in a patient after craniopharyngioma surgery: A case report.
Qi W; Gu F; Wu C
Medicine (Baltimore); 2019 Jan; 98(3):e14101. PubMed ID: 30653131
[TBL] [Abstract][Full Text] [Related]
62. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
63. Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency.
Boot AM; van der Sluis IM; Krenning EP; de Muinck Keizer-Schrama SM
Horm Res; 2009; 71(6):364-71. PubMed ID: 19506395
[TBL] [Abstract][Full Text] [Related]
64. Mortality and reduced growth hormone secretion.
Stochholm K; Christiansen J; Laursen T; Gravholt CH
Horm Res; 2007; 68 Suppl 5():173-6. PubMed ID: 18174740
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of current growth hormone treatments and future therapies.
Ross R
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):48-51. PubMed ID: 19020386
[TBL] [Abstract][Full Text] [Related]
66. Two hot topics in the field of GH therapy: quality of life in hypopituitary adults, and clinical implications of the somatopause. Report from an interactive discussion.
Jørgensen JO
J Endocrinol Invest; 1999; 22(5 Suppl):150-6. PubMed ID: 10442585
[No Abstract] [Full Text] [Related]
67. Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.
Miao Y; Fan K; Peng X; Li S; Chen J; Bai RN; Wei Y; Deng Y; Zhao C; Wu Q; Ge M; Gong J; Wu D
Front Endocrinol (Lausanne); 2023; 14():1241145. PubMed ID: 38027203
[TBL] [Abstract][Full Text] [Related]
68. Current strategies in diagnostics and endocrine treatment of patients with childhood craniopharyngioma during follow-up--recommendations in KRANIOPHARYNGEOM 2000.
Müller HL; Gebhardt U; Etavard-Gorris N; Kolb R; Warmuth-Metz M; Sörensen N
Onkologie; 2005 Mar; 28(3):150-6. PubMed ID: 15772466
[TBL] [Abstract][Full Text] [Related]
69. Metabolic implications of growth hormone therapy.
Perrini S; Carreira MC; Conserva A; Laviola L; Giorgino F
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):79-84. PubMed ID: 19020393
[TBL] [Abstract][Full Text] [Related]
70. Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen).
Plotnick L; Rapaport R; Desrosiers P; Fuqua JS
Pediatr Endocrinol Rev; 2009 Jan; 6 Suppl 2():278-82. PubMed ID: 19337182
[TBL] [Abstract][Full Text] [Related]
71. [CranioNet -- an interdisciplinary strategy for craniopharyngioma].
Reschke K; Busse S; Mohnike K; Buchfelder M; Ranke M; Fahlbusch R; Lehnert H
Dtsch Med Wochenschr; 2006 Apr; 131(15):821-4. PubMed ID: 16607603
[TBL] [Abstract][Full Text] [Related]
72. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.
Jasim S; Alahdab F; Ahmed AT; Tamhane SU; Sharma A; Donegan D; Nippoldt TB; Murad MH
Endocrine; 2017 May; 56(2):267-278. PubMed ID: 27815769
[TBL] [Abstract][Full Text] [Related]
73. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
[TBL] [Abstract][Full Text] [Related]
74. Adults' Adherence to Growth Hormone Replacement in Relation to Medication-Related Beliefs, Coping and Quality of Life - An Exploratory Analysis.
Siegel S; Unger N; Streetz-van der Werf C; Karges W; Schilbach K; Schröder B; Szybowicz J; Sauerwald J; Zopf K; Grzywotz A; Bidlingmaier M; Kirstein C; Sommer H; Strasburger CJ; Kreitschmann-Andermahr I
Front Endocrinol (Lausanne); 2021; 12():680964. PubMed ID: 34108940
[TBL] [Abstract][Full Text] [Related]
75. Growth hormone-induced increases in skeletal muscle mass alleviates the associated insulin resistance in short children born small for gestational age, but not with growth hormone deficiency.
Martin DD; Schweizer R; Schönau E; Binder G; Ranke MB
Horm Res; 2009; 72(1):38-45. PubMed ID: 19571558
[TBL] [Abstract][Full Text] [Related]
76. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma.
Fjalldal S; Holmer H; Rylander L; Elfving M; Ekman B; Osterberg K; Erfurth EM
J Clin Endocrinol Metab; 2013 Aug; 98(8):3253-62. PubMed ID: 23771923
[TBL] [Abstract][Full Text] [Related]
77. Impaired aerobic exercise adaptation in children and adolescents with craniopharyngioma is associated with hypothalamic involvement.
Piguel X; Abraham P; Bouhours-Nouet N; Gatelais F; Dufresne S; Rouleau S; Coutant R
Eur J Endocrinol; 2012 Feb; 166(2):215-22. PubMed ID: 22096113
[TBL] [Abstract][Full Text] [Related]
78. Adult growth hormone deficiency (GHD): an established diagnosis?
Attanasio AF
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):27-32. PubMed ID: 19020382
[TBL] [Abstract][Full Text] [Related]
79. [Hypopituitarism].
Faust M
Dtsch Med Wochenschr; 2006 Jul; 131(30 Suppl 3):S78-81. PubMed ID: 16933197
[No Abstract] [Full Text] [Related]
80. Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up.
Muller HL
Horm Res; 2008; 69(4):193-202. PubMed ID: 18204266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
